Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis USD Growth in Rest of World by Quarter
USD Growth in Rest of World (% USD) (%)
Novartis USD Growth in Rest of World: 35.0% in Q3 2026, down 5.0 pts from a year earlier.
Latest, Q3 2026
35.0%
Period ended Sep 30, 2026
Change on a year earlier
-5.0 pts
40.0% in Q3 2025
History
27 quarters
Since Q1 2020
Sources
27
Documents cited below
Where the Q3 2026 figure comes from
“|| Kisqali | Oncology | HR+/HER2- metastatic breast cancer and early breast cancer | 1 168 | 38 | 653 | 35 | 35 | 1 821 | 37 | 37”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis USD Growth in Rest of World (%), quarterly Q1 2020–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kisqali-row-yoy-usd-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.